THAR Tharimmune
- 2.965
- -0.115-3.73%
Tharimmune News
Express News | Tharimmune Reports Type C Meeting With FDA For Phase 2 Program For TH104
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersScinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:ND
Express News | Tharimmune Receives Notice From Nasdaq Confirming Compliance With Minimum Bid Price Requirement
Express News | Tharimmune : Received Notice From Nasdaq That Co Has Regained Compliance With Minimum Bid Price Requirement
Tonix TNXP Reverse Stock Split 1-for-32; Tharimmune THAR Offering
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and
12 Health Care Stocks Moving In Monday's Intraday Session
GainersSeres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increase
Express News | Tharimmune Shares Are Trading Lower After the Company Announced That It Entered Into an ATM Agreement With Rodman & Renshaw to Sell Common Stock at Market Price
Why Tharimmune (THAR) Shares Are Getting Hammered
Tharimmune Inc (NASDAQ:THAR) shares are trading lower by 30% to $3.60 during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement with Rodman &
Express News | Reported Friday, "Tharimmune Enters ATM Agreement With Rodman & Renshaw To Sell Common Stock At Market Price, Paying 3% Commission On Sales"
Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024, Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo and Tharimmune - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.The panorama of scienti
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Tharimmune To Carry Out 1-for-15 Reverse Stock Split On May 28th, 2024
May 24th - $Tharimmune(THAR.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from May 28th, 2024.$Tharimmune(THAR.US)$ rose
Express News | Tharimmune Shares Are Trading Lower After the Company Announced a 1-for-15 Reverse Stock Split
Why Tharimmune (THAR) Shares Are Moving
Tharimmune Inc (NASDAQ:THAR) shares are trading lower by 16.4% to $0.33 during Wednesday's session after the company announced a 1-for-15 reverse stock split of its common stock effective after tradin
Tharimmune to Implement 1-for-15 Reverse Stock Split
Tharimmune (THAR) said Wednesday it will implement a 1-for-15 reverse stock split after the close of trading on Nasdaq on Friday. The company said its shares will trade on a post-split basis under the
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
Tharimmune | 10-Q: Quarterly report
Express News | Tharimmune Announced An Option Agreement For An Exclusive License With Washington University In St. Louis For Technology Related To Multiple Hybridomas And Antibodies Directed Specifically Towards Human HER2
Express News | Tharimmune Inc: Obtained Rights From Washington University to Develop and Incorporate Human Her2 Directed Antibodies
Analysis
Price Target
No Data
